Rinvoq — Medical Mutual

Initial criteria

• Patient age ≥ 18 years
• Patient had a 3-month trial of ≥1 TNF inhibitor OR unable to tolerate 3-month trial
• Rinvoq prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• Patient established on therapy ≥ 6 months
• Patient experienced beneficial response measured by objective measure OR symptom improvement such as decreased joint pain, morning stiffness, fatigue, improved function or activities of daily living, or decreased swelling

Approval duration

initial 6 months; renewal 1 year